Survival from high-grade localised extremity osteosarcoma: Combined results and prognostic factors from three European osteosarcoma intergroup randomised controlled trials

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1607-1616

  Whelan, J S ^a   Jinks, R C ^b   McTiernan, A ^a   Sydes, M R ^b   Hook, J M ^b   Trani, L ^a   Uscinska, B ^b   Bramwell, V ^c   Lewis, I J ^d   Nooij, M A ^e   Van glabbeke, M ^f   Grimer, R J ^g   Hogendoorn, P C W ^e   Taminiau, A H M ^e   Gelderblom, H ^e  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c TOM BAKER CANCER CENTRE   (Canada)

^d ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f European Organization for Research   (Belgium)

^g ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Adolescents; Chemotherapy; Osteosarcoma; Randomised controlled trial

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; DRUG MEGADOSE; EUROPE; FEMALE; HISTOPATHOLOGY; HUMAN; LIMB SALVAGE; LIMB TUMOR; LOCALISED EXTREMITY OSTEOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PREOPERATIVE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 84861735150     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr491     Document Type: Article

References (33)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3-13.
2. Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972; 4: 482-510.
3. Bacci G, Longhi A, Versari M et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154-1161.
4. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
5. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with highdose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
6. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
7. Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638.
8. Hogendoorn PC, Athanasou N, Bielack S et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v204-v213.
9. Bramwell VH, Burgers M, Sneath R et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992; 10: 1579-1591.
10. Souhami RL, Craft AW, Van der Eijken JW et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911-917.
11. Hauben EI, Weeden S, Pringle J et al. Does the histological subtype of highgrade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002; 38: 1218-1225.
12. Lewis IJ, Weeden S, Machin D et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol 2000; 18: 4028-4037.
13. Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230.
14. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, New York: John Wiley 1995.
15. Eyre R, Feltbower RG, James PW et al. The epidemiology of bone cancer in 0-39 year olds in northern England, 1981-2002. BMC Cancer 2010; 10: 357.
16. Gatta G, Capocaccia R, Stiller C et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23: 3742-3751.
17. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-1543.
18. Smeland S, Muller C, Alvegard TA et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 488-494.
19. Akatsuka T, Wada T, Kokai Y et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002; 94: 1397-1404.
20. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009; 35: 1030-1036.
21. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12: 423-431.
22. Glasser DB, Lane JM, Huvos AG et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 1992; 69: 698-708.
23. Kawai A, Huvos AG, Meyers PA, Healey JH. Osteosarcoma of the pelvis. Oncologic results of 40 patients. Clin Orthop Relat Res 1998; 348: 196-207.
24. Weeden S, Grimer RJ, Cannon SR et al. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001; 37: 39-46.
25. Bacci G, Ferrari S, Bertoni F et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18: 4016-4027.
26. Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-337.
27. Marina N, Bielack S, Whelan J et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res 2009; 152: 339-353.
28. Smeland S, Bruland OS, Hjorth L et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 2011; 82: 211-216.
29. Anninga JK, Gelderblom H, Fiocco M et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011; doi:10.1016/j.ejca.2011.05.030.
30. Buddingh EP, Anninga JK, Versteegh MI et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010; 54: 216-221.
31. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
32. Andreou D, Bielack SS, Carrle D et al. The influence of tumor- and treatmentrelated factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 2011; 22: 1228-1235.
33. Butow P, Palmer S, Pai A et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol 2010; 28: 4800-4809.